Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences
November 22 2017 - 6:00AM
Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies for cardiometabolic disorders, including dyslipidemia and
NASH, today announced that management will be presenting at the
Piper Jaffray 29th Annual Healthcare Conference, and the LD Micro
10th Annual Main Event Conference.
Presentation Details |
Piper Jaffray 29th Annual Healthcare
Conference |
Date: |
|
Wednesday, November
29 |
Time: |
|
1:00pm Eastern
Time |
Presenter: |
|
Lee Golden MD, Chief
Medical Officer |
Location: |
|
Lotte New York Palace
Hotel, Spellman Room |
|
|
|
LD
Micro 10th Annual Main Event Conference |
Date: |
|
Wednesday, December
6 |
Time: |
|
7:30am Pacific
Time/10:30am Eastern Time |
Presenter: |
|
Dr. Steven Gullans,
Interim Chief Executive Officer |
Location: |
|
Luxe Sunset Bel Air,
Los Angeles, CA, Track #2 |
|
|
|
About GemphireGemphire is a clinical-stage
biopharmaceutical company that is committed to helping patients
with cardiometabolic disorders, including dyslipidemia and
NASH. The Company is focused on providing new treatment
options for cardiometabolic diseases through its complementary,
convenient, cost-effective product candidate gemcabene as add-on to
the standard of care, especially statins, that will benefit
patients, physicians, and payors. Gemphire has initiated 3
clinical trials for homozygous familial hypercholesterolemia
(HoFH), heterozygous familial hypercholesterolemia
(HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe
hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and
NCT02944383, respectively, with a fourth planned trial in NASH to
initiate in the fourth quarter of 2017. Please visit
www.gemphire.com for more information.
Forward Looking Statements Any statements in
this press release about Gemphire’s future expectations, plans and
prospects, including statements about Gemphire’s financial
prospects, future operations and sufficiency of funds for future
operations, clinical development of Gemphire’s product candidate,
expectations regarding future clinical trials, regulatory
submissions and meetings and future expectations and plans and
prospects for Gemphire, expectations regarding operating expenses
and cash used in operations, and other statements containing the
words "believes," "anticipates," "estimates," "expects," "intends,"
"plans," "predicts," "projects," "targets," "may," "potential,"
"will," "would," "could," "should," "continue," “scheduled” and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the success and timing of Gemphire’s
regulatory submissions and pre-clinical and clinical trials;
regulatory requirements or developments; changes to Gemphire’s
clinical trial designs and regulatory pathways; changes in
Gemphire’s capital resource requirements; Gemphire’s ability to
obtain additional financing; Gemphire’s ability to successfully
market and distribute its product candidate, if approved;
Gemphire’s ability to obtain and maintain its intellectual property
protection; and other factors discussed in the "Risk Factors"
section of Gemphire’s Annual Report on Form 10-K for the year ended
December 31, 2016, Gemphire’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2017 and in other filings Gemphire
makes with the SEC from time to time. In addition, the
forward-looking statements included in this press release represent
Gemphire’s views as of the date hereof. Gemphire anticipates
that subsequent events and developments will cause Gemphire’s views
to change. However, while Gemphire may elect to update these
forward-looking statements at some point in the future, Gemphire
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Gemphire’s views as of any date subsequent to the date
hereof.
Contact:Andrew McDonald, Ph.D.LifeSci Advisors,
LLC(646) 597-6987
Jeff Mathiesen, CFOGemphire Therapeutics Inc.(734)-245-1700
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Sep 2023 to Sep 2024